Saudi Arabia Pharmaceutical Market

Saudi Arabia Pharmaceutical Market Size, Market Forecast and Outlook By FMI

Key Takeaways

Metric	Value
Market Size (2025)	USD 11.0 Billion
Market Size (2026)	USD 11.7 Billion
Market Size (2036)	USD 21.6 Billion
CAGR (2026–2036)	6.3%
Incremental Opportunity	USD 9.9 Billion
Leading Product Type (2026)	Prescription Products
Prescription Products Share (2026)	61.6%
Fastest-Growing Segment	CAGR
CAGR CAGR	7.5%

 

Summary of the Saudi Arabia Pharmaceutical Market

• Demand and Growth Drivers
  • Chronic disease treatment is sustaining repeat pharmaceutical demand across major care centers in Saudi Arabia.
  • Pharmacy network expansion is improving medicine access across hospital and retail channels.
  • Specialty treatment use is adding fresh demand across regulated pharmaceutical care pathways.
• Product and Segment View
  • Prescription products lead product demand due to strong physician-led treatment use across chronic and acute care.
  • Other diseases remain the core indication group because medicine use extends across a wide treatment pool outside named major conditions.
  • Hospital pharmacies hold the leading channel position due to strong institutional dispensing across regulated therapy use.
• Geography and Competitive Outlook
  • Mecca province and Riyadh province show the strongest growth outlook as healthcare access and prescription intensity stay high.
  • Eastern province posts healthy expansion as regulated product access stays firm across major care settings.
  • Competition centers on therapy breadth and dependable channel access across hospital and retail supply routes.
• Analyst Opinion
  • Sabyasachi Ghosh, Principal Analyst for Healthcare at FMI, opines, “Saudi Arabia pharmaceutical demand is propelled owing to the therapy availability and steady pharmacy access. Suppliers that support treatment continuity and dependable distribution should hold the strongest position across regulated medicine demand.”
• Saudi Arabia Pharmaceutical Market Value Analysis
  • Recurring chronic therapy is propelling significant demand for  pharmaceuticals in Saudi Arabia.
  • Value stays concentrated in prescription products and institutional dispensing across regulated treatment use.
  • Hospital pharmacies account for the largest revenue share due to strong medicine flow through supervised care settings.
  • Pharmacy access expansion and treatment continuity support the expansion during the forecast.

Saudi Arabia Pharmaceutical Market Definition

This market covers prescription and over-the-counter medicines supplied through hospital pharmacies and retail pharmacy chains along with online pharmacy services in Saudi Arabia. Product scope includes small molecules and biologics along with biosimilars across oral and injectable and topical and intra-nasal routes.

Saudi Arabia Pharmaceutical Market Inclusions

The report covers market sizing for Saudi Arabia and forecast from 2026 to 2036. Revenue splits by Product Type and Drug Type are included along with Route of Administration and Indication and Distribution Channel. Province-level growth comparisons are also covered.

Saudi Arabia Pharmaceutical Market Exclusions

Medical devices and diagnostics are excluded from scope because this report is limited to medicines. Nutraceuticals and cosmetic product are outside scope across the full forecast period in this study. Non-pharmaceutical wellness items and general hospital equipment are not included in this report scope at any stage.

Saudi Arabia Pharmaceutical Market Research Methodology

• Primary Research: Interviewed hospital pharmacists, prescribing physicians, and distributors to test medicine demand patterns.
• Desk Research: Reviewed regulatory records and company disclosures along with disease burden publications tied to Saudi Arabia.
• Market Sizing: Performed therapy mapping and price-volume checks across product classes and pharmacy channels in Saudi Arabia.
• Data Validation: Referred to internal consistency checks and peer review before final forecast confirmation.

Why is the Saudi Arabia Pharmaceutical Market Growing?

• Chronic disease treatment is sustaining repeat pharmaceutical demand across hospital pharmacies and retail pharmacies in Saudi Arabia.
• Pharmacy network expansion is improving medicine access across major provincial care centers.
• Prescription continuity is supporting steady medicine flow across regulated treatment pathways.
• Specialty therapies and OTC availability are adding fresh demand across institutional and retail dispensing channels.

Chronic therapy use creates the main demand base for pharmaceuticals in Saudi Arabia. Prescription medicines move through hospital pharmacies and retail outlets because cardiovascular care and diabetes treatment require recurring therapy. Cancer treatment adds another prescription layer across supervised care. which keeps medicine demand consistent across physician based care and routine refill activity.

Pharmacy access expansion supports another demand factor in the country. Retail pharmacies and online pharmacies are improving medicine availability across provincial treatment pools. Demand gains support from specialty treatment use and from steady access to prescription and OTC medicines across regulated care pathways.

Market Segmentation Analysis

• Prescription Products are expected to account for 61.6% share in 2026 as regulated therapies and chronic treatment use keep prescription flow ahead of OTC demand.
• Small Molecules are projected to represent 68.5% in 2026 owing to established therapies which keep this class in the widest prescription base.
• Oral is expected to hold 51.0% share of route of administration demand in 2026 because routine medicine use across chronic care supports higher dispensing volume through this route.
• Other Diseases are anticipated to account for 26.6% share in 2026 because pharmaceutical use extends across a wide treatment pool outside the named major disease groups.
• Hospital Pharmacies are expected to hold 48.6% share of distribution channel demand in 2026 because supervised therapy access keeps institutional dispensing ahead of other channels.

Saudi Arabia pharmaceutical market is segmented by product type, drug type, route of administration, indication, and distribution channel. Product type includes prescription products and over the counter products. Drug type includes small molecules, biologics, and biosimilars. route of administration includes topical, oral, injectable, intra-nasal, and others. Indication includes cardiovascular diseases, diabetes, cancer, obesity, infectious diseases, and other diseases. Distribution channel includes hospital pharmacies, retail pharmacies, and online pharmacies.

Saudi Arabia Pharmaceutical Market Analysis by Product Type

• Prescription Products are expected to account for 61.6% share of product type demand in 2026 because physician-led treatment and long-duration therapy keep this segment ahead.
• Chronic disease care and regulated dispensing support larger prescription volumes across Saudi Arabia.

Insights into the Over-the-Counter Products Segment

• Over the Counter Products retain a smaller share because self-managed treatment use covers a narrower spend pool than regulated medicines.
• Retail access keeps this segment active across routine pharmacy purchases in Saudi Arabia.

Saudi Arabia Pharmaceutical Market Analysis by Drug Type

• Small Molecules are projected to represent 68.5% share in 2026 as established therapies keep this class in the widest prescription base.
• Chronic treatment volumes and broad product use support continued leadership for this drug class.

Insights into the Biologics Segment

• Biologics are witnessing significant expansion as therapy use is more concentrated across selected disease pools.
• Specialty treatment demand keeps this segment active across institutional care settings.

Saudi Arabia Pharmaceutical Market Analysis by Route of Administration

• Oral is expected to hold 51.0% share of route of administration demand in 2026 because routine medicine use across chronic care supports higher dispensing volume through this route.
• Daily therapy use across hospital and retail channels keeps oral medicines in the largest treatment pool.

Insights into the Injectable Segment

• Injectable therapies keep a smaller share than oral products owing to its increasing demand which is tied more closely to supervised treatment settings.
• Hospital care and specialty treatment support continued demand for this segment during the forecast.

Saudi Arabia Pharmaceutical Market Analysis by Indication

• Other Diseases are anticipated to account for 26.6% share of indication demand in 2026 because pharmaceutical use extends across a wide treatment pool outside the named major disease groups.
• Broad medicine use outside the listed disease groups keeps this indication group ahead of the listed segments.

Insights into the Diabetes Segment

• Diabetes keeps a strong place in the market because Saudi Arabia carries a large chronic care burden that supports recurring medicine use.
• Long-duration therapy supports steady dispensing activity in this segment.

Saudi Arabia Pharmaceutical Market Analysis by Distribution Channel

• Hospital Pharmacies are expected to hold 48.6% share of distribution channel demand in 2026 because supervised therapy access keeps institutional dispensing ahead of other channels.
• Physician based treatment and regulated medicine flow support this leading position across major care settings.

Insights into the Retail Pharmacies Segment

• Retail Pharmacies holds significant share in the market as repeat medicine access outside hospitals supports routine refill activity.
• Pharmacy network expansion drives the market growth across provincial treatment demand.

Saudi Arabia Pharmaceutical Market Drivers, Restraints, and Opportunities

• Chronic-care demand supports repeat prescription flow across diabetes and cardiovascular therapy lines in Saudi Arabia.
• Pricing controls restrain value capture across tender-led and reimbursed medicine lines in selected treatment groups.
• Online pharmacy expansion opens added fulfillment capacity for refill-driven medicine demand across urban and developing provincial centers.

Prescription depth supports market expansion because chronic disease treatment keeps repeat medicine use active across Saudi Arabia. Pharmacy access is improving product reach across large provincial centers and across smaller demand pools. Pricing discipline and formulary controls limit full value realization across some therapy lines in the Saudi market.

Chronic Therapy Demand

Chronic care treatment keeps pharmaceutical consumption active across major disease pools in Saudi Arabia. Repeat medicine use across hospital care and refill activity supports steady demand for prescription products.

Pricing Discipline and Formulary Control

Pricing discipline limits product realization across therapeutic classes in Saudi Arabia. Reimbursement limits and formulary controls keep market expansion measured even as treatment need stays firm.

Retail and Online Pharmacy Expansion

Retail and online pharmacy growth supports wider medicine access across provincial treatment pools. Stronger channel reach improves product availability and supports future expansion across regulated pharmaceutical care.

Regional Analysis

Province	CAGR through 2036
Mecca Province	7.5%
Riyadh Province	7.1%
Eastern Province	5.9%
Asir Province	5.3%
Jazan Province	3.6%
Rest of Saudi Arabia	4.4%

Source: Future Market Insights analysis.

Analysis of Saudi Arabia Pharmaceutical Market by Key Countries

• Mecca Province is projected to record 7.5% CAGR through 2036 as dense care access and pilgrimage-linked patient traffic keep medicine turnover high.
• Riyadh Province is expected to post 7.1% CAGR due to capital-city hospital density and specialist treatment access supporting high prescription flow.
• Eastern Province is forecast to expand at 5.9% CAGR since established urban care centers sustain steady regulated medicine use.
• Asir Province is set to advance at 5.3% CAGR because treatment access is improving across local care networks and refill use is rising.
• Jazan Province is projected to register 3.6% CAGR because medicine access is improving from a lower infrastructure base.
• Rest of Saudi Arabia is expected to grow at 4.4% CAGR because pharmacy availability is spreading across emerging provincial treatment pools.

Province growth differs with healthcare concentration and pharmacy access. Mecca Province and Riyadh Province lead the pace because prescription intensity stays high. Jazan Province and the Rest of Saudi Arabia move at a slower rate because infrastructure depth and channel reach are less developed.

Demand outlook for Saudi Arabia Pharmaceutical Market in Mecca Province

Healthcare concentration lifts pharmaceutical demand in Mecca Province across chronic and acute care. Demand in Mecca Province is expected to rise at a 7.5% CAGR through 2036 because hospital access and retail pharmacy reach support recurring medicine use.

• Hospital access supports steady medicine flow across major care settings in Mecca Province.
• Retail pharmacy reach improves product access across daily treatment needs in the province.
• Recurring medicine use keeps pharmaceutical demand active across chronic and acute care.

Future outlook for Saudi Arabia Pharmaceutical Market in Riyadh Province

Healthcare infrastructure supports pharmaceutical demand in Riyadh Province across regulated treatment pathways. Industry expansion in Riyadh Province is projected to post a 7.1% CAGR through 2036 because prescription volumes stay high and institutional access remains firm.

• Dense healthcare infrastructure supports prescription medicine use across Riyadh Province.
• Institutional channels keep regulated therapy access active across the province.
• Retail medicine availability supports recurring treatment demand in daily care.

Opportunity analysis of Saudi Arabia Pharmaceutical Market in Eastern Province

Stable care demand supports pharmaceutical use in Eastern Province across major treatment settings. Demand in Eastern Province is expected to expand at a 5.9% CAGR through 2036 because prescription use stays firm and regulated product access remains wide.

• Major care settings keep prescription demand active across Eastern Province.
• Regulated product access supports medicine availability through core channels.
• Stable healthcare demand keeps the provincial market on a steady path.

In-depth analysis of Saudi Arabia Pharmaceutical Market in Asir Province

Treatment access is improving in Asir Province across developing care networks. Industry sales in Asir Province are forecast to record a 5.3% CAGR through 2036 because prescription products and OTC products see rising repeat demand.

• Developing care networks improve medicine access across Asir Province.
• Prescription products support recurring treatment demand in the province.
• OTC products add steady volume across routine pharmacy use.

Sales analysis of Saudi Arabia Pharmaceutical Market in Jazan Province

Medicine access expansion supports pharmaceutical demand in Jazan Province across regulated therapy use. Demand in Jazan Province is projected to rise at a 3.6% CAGR through 2036 because stable medicine use continues through a more limited care base.

• Medicine access is widening across Jazan Province through pharmacy channels.
• Regulated therapies keep steady use across the provincial treatment base.
• Infrastructure depth keeps growth below the pace seen in Mecca province and Riyadh province.

Future outlook for Saudi Arabia Pharmaceutical Market in Rest of Saudi Arabia

Emerging provincial treatment pools support pharmaceutical demand across the Rest of Saudi Arabia. Demand across the Rest of Saudi Arabia is projected to rise at a 4.4% CAGR through 2036 because pharmacy access expands and medicine penetration improves.

• Emerging treatment pools support gradual medicine demand across smaller provincial markets.
• Pharmacy access expansion improves product availability outside the largest care centers.
• Medicine penetration continues to rise across developing provincial channels.

Competitive landscape and Strategic Positioning

• Competition is moderately concentrated around multinational and regional pharmaceutical suppliers with broad therapy coverage.
• Leading firms compete on therapy breadth and prescription continuity. Channel reach and product availability shape supplier standing across hospital and retail demand.
• Focused suppliers gain ground through selective therapy lines or localized access across Saudi Arabia.
• Entry stays selective because prescribing trust and dependable supply are required across regulated pharmaceutical channels.

Established multinational suppliers hold an advantage because hospital pharmacies and retail outlets rely on dependable availability across recurring treatment cycles. Merck & Co. holds strong placement through therapy depth and brand familiarity across institutional and retail demand channels. Pfizer and Astellas compete through wide product coverage and steady prescription-led presence in structured care pathways.

Scale leaders defend their position based on therapeutic importance and strong distribution systems across Saudi Arabia. Wider disease-area coverage helps these suppliers stay active across chronic care and specialty care. Multi-line availability strengthens supplier standing in hospital pharmacies and retail pharmacies that favor continuity in approved medicine flow.

Focused suppliers compete through narrower therapy coverage or localized access in selected treatment lines. This approach can support placement in specific prescribing relationships or targeted product pools. A smaller operational footprint can weaken their standing during formal supplier review across larger dispensing networks.

Hospital pharmacies shape a large share of medicine flow in Saudi Arabia and this keeps supplier review tied to channel reliability. Retail pharmacies and online pharmacies add another demand layer through repeat medicine access. Pricing power stays measured in standard product lines unless supply continuity or stronger therapy relevance supports a firmer position.

Key Companies in the Saudi Arabia Pharmaceutical Market

Company positions reflect therapy breadth and distribution strength across prescription and OTC pharmaceutical lines.

• Multinational Portfolio Leaders: Merck & Co. and Pfizer and Astellas hold strong positions through therapy-area depth and prescription-led market presence. GSK and AstraZeneca add scale through broad pharmaceutical coverage in Saudi Arabia.
• Regional and Domestic Suppliers: Jamjoom Pharmaceuticals and Hikma-Jazeera Pharmaceutical Industries and Saudi Pharmaceutical Industries and SAJA Pharmaceutical support market coverage through active presence across Saudi pharmaceutical channels. Batterjee Pharmaceutical Factory and Al Razi Pharmaceutical Company add further depth to the listed company pool.
• Diversified International Suppliers: Novartis AG and Takeda Pharmaceutical Company Limited and Pharmascience Inc. and Axantia Holding broaden the competitive set through wider product portfolios. Hakeem Pharma and Elixir Pharmaceutical Co. Ltd. add depth to the focused supplier base.

Competitive Benchmarking: Saudi Arabia Pharmaceutical Market

Company	Therapy Portfolio Depth	Channel Access	Prescription Market Presence	Geographic Footprint
Merck & Co., Inc.	High	High	High	Global
Pfizer Inc.	High	High	High	Global
Astellas Pharma	High	Moderate	High	Global
GSK Plc.	Moderate	Moderate	Moderate	Global
Astra Zeneca Plc.	Moderate	Moderate	Moderate	Global
Jamjoom Pharmaceuticals Co.	Moderate	Moderate	Moderate	Regional
Hikma-Jazeera Pharmaceutical Industries	Moderate	Moderate	Moderate	Regional

Source: Future Market Insights analysis based on the supplied market model and covered company positioning in the Saudi Arabia pharmaceutical report.

Key Developments in the Saudi Arabia Pharmaceutical Market

• In November 2025, KAIMRC and Flagship Pioneering entered into a strategic partnership to advance early-phase clinical research for novel medicines in Saudi Arabia, strengthening the country's biopharmaceutical research ecosystem.
• In January 2026, ImmunityBio announced that the Saudi Food and Drug Authority (SFDA) granted accelerated approval for ANKTIVA in combination with checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer.
• In October 2024, NUPCO, PIF-owned Lifera, and Novo Nordisk agreed to localize the production of up to seven insulin products in Saudi Arabia, while a ministerial visit to Denmark on May 9, 2025, further advanced localization efforts for insulin, GLP-1 therapies, and biotherapeutics in collaboration with Novo Holdings.
• In 2025, Pfizer and Lifera signed a memorandum of understanding to support local pharmaceutical manufacturing and workforce development, while Lifera also announced a potential joint venture with Jamjoom Pharma at the Global Health Exhibition in October 2025.
• In December 2025, Saudi Arabia announced that NUPCO's 2026 tenders would reject foreign bids where an SFDA-approved local alternative is available. Government procurement accounts for approximately 54% of the country's SAR 30 billion pharmaceutical market, while Sudair Industrial City expanded to 421 facilities following 12% growth in 2024.
• The Saudi Food and Drug Authority (SFDA) implemented version 1.1 of its pharmacoeconomic evaluation guideline on July 1, 2025, making full economic evaluations mandatory for pharmaceutical assessments.

Key Players in the Saudi Arabia Pharmaceutical Market

Major Global Players

• Merck & Co., Inc.
• Pfizer Inc.
• Astellas Pharma
• GSK Plc.
• Astra Zeneca Plc.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Pharmascience Inc.

Regional and Domestic Players

• Jamjoom Pharmaceuticals Co.
• Al Razi Pharmaceutical Company
• Hakeem Pharma
• Elixir Pharmaceutical Co. Ltd.
• Hikma-Jazeera Pharmaceutical Industries
• Saudi Pharmaceutical Industries (SPI)
• SAJA Pharmaceutical
• Batterjee Pharmaceutical Factory
• Axantia Holding

Report Scope and Coverage

Item	Value
Estimated market value in 2025	USD 11.0 billion
Expected market value in 2026	USD 11.7 billion
Forecast market value in 2036	USD 22.9 billion
CAGR for 2026 to 2036	6.3%
Quantitative units	USD billion
Market definition	Prescription and over-the-counter pharmaceutical products supplied across hospital pharmacies and retail pharmacy chains and online channels in Saudi Arabia.
Product Type segmentation	Prescription Products and Over-The-Counter Products (OTC)
Drug Type segmentation	Small Molecules and Biologics and Biosimilars
Route of Administration segmentation	Topical and Oral and Injectable and Intra-Nasal and Others
Indication segmentation	Cardiovascular Diseases and Diabetes and Cancer and Obesity and Infectious Diseases and Other Diseases
Distribution Channel coverage	Hospital Pharmacies and Retail Pharmacies and Online Pharmacies
Provinces covered	Mecca Province and Riyadh Province and Eastern Province and Asir Province and Jazan Province and Rest of Saudi Arabia
Key companies profiled	Merck & Co., Inc. and Pfizer Inc. and Astellas Pharma and GSK Plc. and Astra Zeneca Plc. and Jamjoom Pharmaceuticals Co. and others
Forecast period	2026 to 2036
Historical reference year	2025
Approach	Hybrid top-down and bottom-up market modeling validated through primary interviews and demand triangulation across therapy volumes and provincial access patterns.

Source: Future Market Insights analysis.

Saudi Arabia Pharmaceutical Market Breakdown by Product Type, Drug Type, Route of Administration, Indication, and Distribution Channel

Saudi Arabia Pharmaceutical Market Analysis by Product Type

• Prescription Products
• Over The Counter Products (OTC)

Saudi Arabia Pharmaceutical Market Analysis by Drug Type

• Small Molecules
• Biologics
• Biosimilars

Saudi Arabia Pharmaceutical Market Analysis by Route of Administration

• Topical
• Oral
• Injectable
• Intra-Nasal
• Others

Saudi Arabia Pharmaceutical Market Analysis by Indication

• Cardiovascular Diseases
• Diabetes
• Cancer
• Obesity
• Infectious Diseases
• Other Diseases

Saudi Arabia Pharmaceutical Market Analysis by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Saudi Arabia Pharmaceutical Market Analysis by Province

• Mecca Province
• Riyadh Province
• Eastern Province
• Asir Province
• Jazan Province
• Rest of Saudi Arabia

Research sources and bibliography

1. Ministry of Health. (2024, November 21). Saudi health minister to embark on official visit to Greece.
2. Ministry of Health. (2025, July 15). Biotechnology powers Saudi Arabia’s journey from genomics to pharmaceutical security and a sustainable future.
3. Public Health Authority. (2024). High-impact interventions to reduce non-communicable diseases SMR.
4. Almakrob, A. Y., & Alduais, A. (2025). Depression and anxiety in the Saudi population: Epidemiological profiles from health surveys and mental health services. INQUIRY: The Journal of Health Care Organization, Provision, and Financing, 62.
5. ImmunityBio, Inc. (2026, January 14). Saudi FDA grants accelerated approval to ImmunityBio’s ANKTIVA® in combination with checkpoint inhibitors for metastatic non-small cell lung cancer.
6. Flagship Pioneering. (2025, November 19). King Abdullah International Medical Research Center and Flagship Pioneering announce strategic partnership to expand clinical research of novel medicines in Saudi Arabia.

The bibliography is provided for reader reference.

This Report Answers

• How large can the Saudi Arabia Pharmaceutical Market become by 2036?
• Which segment leads 2026 demand across Product Type and Drug Type and Route of Administration and Indication and Distribution Channel?
• Why prescription products and small molecules keep the largest 2026 share positions in Saudi Arabia?
• Which provinces post the fastest expansion and what conditions support their CAGR outlook through 2036?
• How channel structure influences medicine availability across hospital pharmacies and retail pharmacy chains and online services?
• Which companies hold the clearest competitive positions across Saudi pharmaceutical supply lines during the forecast period?